MentionFox
Home › Executive changes › Jasper Therapeutics, Inc.
Leadership changes · SEC Form 8-K, Item 5.02

Jasper Therapeutics, Inc. executive changes

Every leadership change Jasper Therapeutics, Inc. reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings2
Appointments named1
Departures named1
Latest filing2026-07-17

Jasper Therapeutics, Inc. filed 2 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-17. Between them they name 2 people, with 1 appointment and 1 departure. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-07-17 · 8-K

Appointed: Patrick Crutcher, Director

Appointment of Director In accordance with the Merger Agreement, on July 16, 2026, the Board appointed Patrick Crutcher, age 41, to the Board as a Class I director, effective as of immediately after the Effective Time.
Filed 2026-05-21 · 8-K

Departing: Christian Nolet

On May 15, 2026 (the "Notice Date"), Christian Nolet informed the Board of Directors (the "Board") of Jasper Therapeutics, Inc. (the "Company") that he is resigning from the Board and the committees of the Board on which he serves, effective as of the Notice Date.
Hiring for a seat like this?

Find people with the same kind of experience as the Director at Jasper Therapeutics, Inc., with the record behind each one.

Find candidates like Director at Jasper Therapeutics, Inc.
Selling to Jasper Therapeutics, Inc.?

New leaders review vendors and budgets in their first months. Get an alert the next time Jasper Therapeutics, Inc. is in the news or changes leadership.

Get an alert when Jasper Therapeutics, Inc. changes leadership

Tools for this story

Each opens in a new tab, filled in for Jasper Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/jasper-therapeutics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2
Jasper Therapeutics, Inc. (JSPR) executive changes: Patrick Crutcher appointed, Director. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/jasper-therapeutics